Syngene International Limited

Equities

SYNGENE

INE398R01022

Biotechnology & Medical Research

Market Closed - NSE India S.E. 06:43:37 2024-02-23 am EST 5-day change 1st Jan Change
744.5 INR -0.49% Intraday chart for Syngene International Limited -2.64% +6.14%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Jefferies Adjusts Syngene International’s Price Target to INR690 From INR770, Keeps at Hold MT
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit MT
Transcript : Syngene International Limited, Q3 2024 Earnings Call, Jan 25, 2024
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024 CI
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant MT
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion. CI
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China RE
Syngene International COO Steps Down MT
Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024 CI
Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director CI
Transcript : Syngene International Limited, Q2 2024 Earnings Call, Oct 18, 2023
Syngene International's Consolidated Profit Jumps in Fiscal Q2; Shares Slump 7% MT
Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023 CI
Syngene International Limited(NSEI:SYNGENE) added to FTSE All-World Index CI
Jefferies Adjusts Syngene International’s Price Target to INR960 From INR750, Keeps at Buy MT
Syngene International Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023 CI
Transcript : Syngene International Limited, Q1 2024 Earnings Call, Jul 27, 2023
Transcript : Syngene International Limited - Shareholder/Analyst Call
Syngene International Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Strides Pharma Unit to Sell Manufacturing Facility in Bengaluru, India to Syngene; Shares Drop 3% MT
Syngene to Acquire Biologics Manufacturing Unit for $86 Million MT
Syngene International Limited Announces the Acquisition of Unit 3 Biologics Manufacturing Facility in Bangalore, India, from Stelis Biopharma Limited CI
Syngene International Limited agreed to acquire Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 7 billion. CI
Chart Syngene International Limited
More charts
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
744.5 INR
Average target price
748.7 INR
Spread / Average Target
+0.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Syngene International Limited - NSE India S.E.
  4. News Syngene International Limited
  5. Syngene International's Consolidated Profit Jumps in Fiscal Q2; Shares Slump 7%
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW